Overview

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Status:
Completed
Trial end date:
2019-01-25
Target enrollment:
Participant gender:
Summary
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Anne Chang
Treatments:
Antibodies, Monoclonal